People who have been diagnosed with obstructive sleep apnoea could be at increased risk of adverse outcomes from COVID-19, according to a study from the University of Warwick. The conclusion is drawn from a systematic review of studies that reported outcomes for COVID-19 patients that were also diagnosed with obstructive sleep apnoea.
A study in mice has found that the estimated ten trillion bacteria living in your digestive system may shape your metabolism, as well as directly influencing biological processes from bowel movements to behaviour. Researchers in Daniel Mucida's Laboratory of Mucosal Immunology at Rockefeller University, have identified a particular type of gut neuron that controls blood sugar levels, influencing appetite.
A novel hydrogel platform technology to treat overweight, obesity and other chronic metabolic diseases, was the subject pf one oral presentation and two poster presentations showcasing notable efficacy data for Plenity (Gelesis 100) at the European and International Congress on Obesity (ECO-ICO 2020).
GI Windows Medical, a clinical-stage, privately-held medical device company, has raised US$16.4 million Series A-1 financing. The financing attracted Johnson & Johnson Innovation along with Sonder Capital, GT Healthcare, JC Investco and one additional strategic investor. In addition to the institutional financing, GI Windows also received investments from existing shareholders as well as new investors, the Kennedy Trust and Coleman Trust.
Young adults who have experienced weight stigma have more distress and maladaptive eating behaviours during the pandemic, regardless of their body size. Research from the UConn Rudd Center for Food Policy and Obesity and the University of Minnesota shows that young adults who experienced weight stigma before the pandemic have higher levels of depressive symptoms, stress, eating as a coping strategy, and are more likely to binge-eat during COVID-19, compared to those who have not experienced weight stigma.